爱科百发赴港IPO：年亏9163万，尚未产品商业化

8
1
Favorite

爱科百发赴港IPO：年亏9163万，尚未产品商业化

格隆汇2021-07-06

上海爱科百发生物医药技术股份有限公司（以下简称“爱科百发”）向港交所递交上市招股说明书，美银、中信证券和华兴资本担任联席保荐人，德勤为其审计师。自2014年成立以来，爱科百发共开展了8轮融资。在最新的C+轮融资中，2021年1月，公司引入高瓴创投、TPG联合领投，万容红土、瑞华投资、燕园姚商等8家投资机构参与投资，融资后公司估值达到38.7亿元。 IPO前，公司股权架构方面，Jim Zhen ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

神秘紫
·2021-07-06
Nice
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2149333886?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","is_english":false,"pubTime":"2021-07-06 18:35","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2149333886","market":"hk","top_or_hot":-1,"title":"爱科百发赴港IPO：年亏9163万，尚未产品商业化","media":"格隆汇","content":"<div>\n<p>上海爱科百发生物医药技术股份有限公司（以下简称“爱科百发”）向港交所递交上市招股说明书，美银、中信证券和华兴资本担任联席保荐人，德勤为其审计师。\n自2014年成立以来，爱科百发共开展了8轮融资。在最新的C+轮融资中，2021年1月，公司引入高瓴创投、TPG联合领投，万容红土、瑞华投资、燕园姚商等8家投资机构参与投资，融资后公司估值达到38.7亿元。\nIPO前，公司股权架构方面，Jim Zhen ...</p>\n\n<a href=\"http://www.gelonghui.com/p/473496\">Source Link</a>\n\n</div>\n","source":"gelonghui_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>爱科百发赴港IPO：年亏9163万，尚未产品商业化</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n爱科百发赴港IPO：年亏9163万，尚未产品商业化\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 18:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.gelonghui.com/p/473496><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>上海爱科百发生物医药技术股份有限公司（以下简称“爱科百发”）向港交所递交上市招股说明书，美银、中信证券和华兴资本担任联席保荐人，德勤为其审计师。\n自2014年成立以来，爱科百发共开展了8轮融资。在最新的C+轮融资中，2021年1月，公司引入高瓴创投、TPG联合领投，万容红土、瑞华投资、燕园姚商等8家投资机构参与投资，融资后公司估值达到38.7亿元。\nIPO前，公司股权架构方面，Jim Zhen ...</p>\n\n<a href=\"http://www.gelonghui.com/p/473496\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSI","symbol_name":"恒生指数","start_time":0,"source_url":"http://www.gelonghui.com/p/473496","article_id":"2149333886","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2149333886","pubTimestamp":1625567714,"sourceInfo":{"source_id":"gelonghui_highlight","name":"格隆汇"},"weMediaInfo":null,"summary":"上海爱科百发生物医药技术股份有限公司（以下简称“爱科百发”）向港交所递交上市招股说明书，美银、中信证券和华兴资本担任联席保荐人，德勤为其审计师。\n自2014年成立以来，爱科百发共开展了8轮融资。在最新","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HSI":"恒生指数"},"translate_title":"Aike Baifa's IPO in Hong Kong: The annual loss is 91.63 million, and the products have not yet been commercialized","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/e482148e0911aecf3e1016644cc95210","symbols_score_info":{"HSI":0.9},"content_text":"上海爱科百发生物医药技术股份有限公司（以下简称“爱科百发”）向港交所递交上市招股说明书，美银、中信证券和华兴资本担任联席保荐人，德勤为其审计师。\n自2014年成立以来，爱科百发共开展了8轮融资。在最新的C+轮融资中，2021年1月，公司引入高瓴创投、TPG联合领投，万容红土、瑞华投资、燕园姚商等8家投资机构参与投资，融资后公司估值达到38.7亿元。\nIPO前，公司股权架构方面，Jim Zhen WU博士通过全资拥有的Prots Excel持股19.58%，通过全资拥有的Million Joy持股4.99%，通过持股99.99%的爱尔凯持股2.65%，合计拥有股份27.22%；4个雇员持股计划平台合计持股7.96%；机构投资者中，启明创投持股占比最大，达11.11%；泰福资本通过Golden Trend、HarmonySky合计持股7.84%；晨兴资本通过耀阳生物科技持股7.51%；高瓴资本、TPG各持有公司4.99%股权，除此之外，其他股东持股约31%。\n\n业务方面，爱科百发作为一家创新生物制药公司，专注于发现和开发新型疗法，以应对呼吸系统和肺部疾病方面未被满足的医疗需求。\n目前，爱科百发已开发了9种候选药物的产品管线，核心产品包括以Ziresovir为首的三项药物RSV药品组合，以及以AK3280为重点的三项药物的抗纤维化药品组合。除此之外，公司在肺纤维化和炎症、肝脏及其他疾病领域还有多款在研药品处于临床前或临床阶段，离上市还有很长的时间。\n\n2020年，全球RSV药物市场为18亿美元，预计到2030年将增长至18亿美元，年复合增长率为21.4%。目前，市场上还没有有效的RSV治疗方法。而爱科百发正研发的Ziresovir是全球首款成功完成住院婴幼儿II期概念验证临床试验的RSV药物。\n临床试验显示，多剂量服用Ziresovir后，患者体内有强抗病毒作用，与安慰剂组相比，药物治疗组的病毒载量最多减少98%，显示出良好的疗效及安全性。目前，针对儿童RSV的AK0529药物（Ziresovir）已处于临床III期，预计将于2022年下半年向国家药监局提交新药申请，并于2023年在国内上市。\n\n就目前而言，爱科百发尚未有产品上市商业化，仍处于亏损状态。招股书显示，公司2019年无营收，2020年营收为1415万元；相对应的净亏损分别为1.12亿元、9162.8万元。截至2021年一季度，公司亏损规模较上年同期扩大1倍至3525.8万元。可以预见的是，短时间内，公司“烧钱”研发的状况仍将持续。","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":157350240,"gmtCreate":1625568030480,"gmtModify":1703743904325,"author":{"id":"4087179126205260","authorId":"4087179126205260","name":"神秘紫","avatar":"https://static.tigerbbs.com/8a1a172d1a6a97bd0845231616bcef1e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4087179126205260","idStr":"4087179126205260"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157350240","repostId":2149333886,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":8,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}